Diabetes: GI Dynamics inks research deals with Medtronic, GlaxoSmithKline

January 9, 2013 by MassDevice staff

GI Dynamics lands research partnerships with Medtronic and GlaxoSmithKline, evaluating the relationship between EndoBarrier intestinal liner treatment and patient glucose levels and hormonal changes.

GI Dynamics logo

Weight loss devices maker GI Dynamics (ASX:GID) announced new research partnerships with GlaxoSmithKline (NYSE:GSK) and Medtronic (NYSE:MDT), looking for new data on its EndoBarrier intestinal liner.

The partnership with Medtronic will examine how treatment with EndoBarrier affects continuous glucose levels and the research with GlaxoSmithKline will look at hormonal changes as a result of the implant.

Sign up to get our free newsletters delivered right to your inbox.

Additional details on the partnerships are confidential, according to a press release.